{"id":"W4415535704","doi":"10.1016/j.jtct.2025.10.024","title":"CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Takeda Oncology; U.S. Public Health Service; Health Resources and Services Administration; National Institutes of Health; Jazz Pharmaceuticals; Medac; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Gateway for Cancer Research; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Clinical trial; Cytokine release syndrome; Safety monitoring; Food and drug administration; Data monitoring committee; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00366981,0.0002277138,0.0007506313,0.0001381607,0.0001842471,0.0001050291,0.0002275995,0.0001621572,0.002687221],"category_scores_gemma":[0.00008408568,0.0001349667,0.000128276,0.0002722885,0.000327612,0.0001070699,0.00004643542,0.0004237416,0.000007193689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001721849,"about_ca_system_score_gemma":0.0001397835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003218219,"about_ca_topic_score_gemma":0.0005982639,"domain_scores_codex":[0.9967251,0.001333195,0.0008129034,0.0005508625,0.0003376531,0.0002402799],"domain_scores_gemma":[0.9966204,0.002310047,0.0001618698,0.0006971614,0.00006702972,0.0001434693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1462869,0.0004468791,0.2443269,0.000681552,0.001885072,0.0006590302,0.004637138,0.00000221015,0.07851907,0.000241547,0.003304699,0.5190089],"study_design_scores_gemma":[0.1131431,0.000878098,0.720825,0.001632837,0.002148903,0.00005615614,0.002448143,0.003678722,0.03746702,0.0010842,0.1157113,0.0009265142],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830201,0.00526421,0.0005944525,0.00647104,0.0002243195,0.001376416,0.0003729506,0.00005829082,0.00261825],"genre_scores_gemma":[0.8607686,0.1181489,0.0003883218,0.004346793,0.0004491888,0.00009198425,0.001230747,0.00004101003,0.0145345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5180824,"threshold_uncertainty_score":0.9982244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1245555539661076,"score_gpt":0.4200015351121382,"score_spread":0.2954459811460307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}